PMID- 37329988
OWN - NLM
STAT- MEDLINE
DCOM- 20231108
LR  - 20231108
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
VI  - 173
DP  - 2023 Aug
TI  - Effect of DHCR7 for the co-occurrence of hypercholesterolemia and vitamin D 
      deficiency in type 2 diabetes: Perspective of health prevention.
PG  - 107576
LID - S0091-7435(23)00156-1 [pii]
LID - 10.1016/j.ypmed.2023.107576 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a complex disease caused by multiple factors, 
      which are often accompanied by the disorder of glucose and lipid metabolism and 
      the lack of vitamin D.Over the years, researchers have conducted numerous studies 
      into the pathogenesis and prevention strategies of diabetes. In this study, 
      diabetic SD rats were randomly divided into type 2 diabetes group, vitamin D 
      intervention group, 7-dehydrocholesterole reductase (DHCR7) inhibitor 
      intervention group, simvastatin intervention group, and naive control group. 
      Before and 12 weeks after intervention, liver tissue was extracted to isolate 
      hepatocytes. Compared with naive control group, in the type 2 diabetic group 
      without interference, the expression of DHCR7 increased, the level of 25(OH)D(3) 
      decreased, the level of cholesterol increased. In the primary cultured naive and 
      type 2 diabetic hepatocytes, the expression of genes related to lipid metabolism 
      and vitamin D metabolism were differently regulated in each of the 5 treatment 
      groups. Overall, DHCR7 is an indicator for type 2 diabetic glycolipid metabolism 
      disorder and vitamin D deficiency. Targeting DHCR7 will help with T2DM 
      therapy.The management model of comprehensive health intervention can timely 
      discover the disease problems of diabetes patients and high-risk groups and 
      reduce the incidence of diabetes.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Sun, Lijie
AU  - Sun L
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Lu, Jixuan
AU  - Lu J
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Yao, Dengju
AU  - Yao D
AD  - School of Computer Science and Technology, Harbin University of Science and 
      Technology, Harbin, China.
FAU - Li, Xinyu
AU  - Li X
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Cao, Yan
AU  - Cao Y
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Liu, Jiangwen
AU  - Liu J
AD  - Department of Endocrinology, Southern University of Science and Technology 
      Hospital, Shenzhen, China.
FAU - Zheng, Tiansheng
AU  - Zheng T
AD  - Department of Endocrinology, Southern University of Science and Technology 
      Hospital, Shenzhen, China.
FAU - Wang, Huihui
AU  - Wang H
AD  - Department of Endocrinology, Qiqihar First Hospital, Qiqihar, China.
FAU - Zhan, Xiaorong
AU  - Zhan X
AD  - Department of Endocrinology, First Affiliated Hospital of Harbin Medical 
      University, Harbin, China; Department of Endocrinology, Southern University of 
      Science and Technology Hospital, Shenzhen, China. Electronic address: 
      xiaorongzhandoctor@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230615
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - EC 1.- (Oxidoreductases)
RN  - EC 1.3.- (Oxidoreductases Acting on CH-CH Group Donors)
RN  - 1406-16-2 (Vitamin D)
RN  - EC 1.3.1.21 (7-dehydrocholesterol reductase)
SB  - IM
MH  - Animals
MH  - Rats
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - *Hypercholesterolemia
MH  - Oxidoreductases
MH  - *Oxidoreductases Acting on CH-CH Group Donors/genetics/metabolism
MH  - Rats, Sprague-Dawley
MH  - Vitamin D/therapeutic use
MH  - *Vitamin D Deficiency
OTO - NOTNLM
OT  - 7-dehydrocholesterol reductase
OT  - Expression of genes
OT  - Glycolipid metabolism disorder
OT  - Type 2 diabetes mellitus
OT  - Vitamin D deficiency
COIS- Declaration of Competing Interest None.
EDAT- 2023/06/18 01:07
MHDA- 2023/10/23 00:42
CRDT- 2023/06/17 19:13
PHST- 2023/05/04 00:00 [received]
PHST- 2023/05/29 00:00 [revised]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/10/23 00:42 [medline]
PHST- 2023/06/18 01:07 [pubmed]
PHST- 2023/06/17 19:13 [entrez]
AID - S0091-7435(23)00156-1 [pii]
AID - 10.1016/j.ypmed.2023.107576 [doi]
PST - ppublish
SO  - Prev Med. 2023 Aug;173:107576. doi: 10.1016/j.ypmed.2023.107576. Epub 2023 Jun 
      15.